[Somatostatin prophylaxis following cephalic duodenopancreatectomy].
This study was aimed at assessing the value of prophylactic somatostatin after cephalic duodenopancreatectomy. A randomized prospective study was undertaken using two groups of patients, one with prophylactic somatostatin (4.5 mg daily in continuous perfusion for 7 days postoperatively), known as group I, and group II, which did not receive somatostatin. During a five-year period, from April 1989 to April 1994, we performed 35 duodenopancreatectomies, of which 21 belonged to group I and 14 to group II. We found a lower incidence of pancreatic anastomosis fistulae in group I (9.5% vs 35.7%; p < 0.05). We did not find any correlation between prophylaxis with somatostatin and the appearance of other complications or postoperative mortality. The mean time of fistula closure in group I was 5 days while that of group II was 19.2 days. In conclusion, the administration of prophylactic somatostatin after cephalic duodenopancreatectomy reduces the incidence and duration of pancreatic fistula.
Beguiristain
A
A
Dpto. de Cirugía General, Clínica Universitaria de Navarra, Pamplona.
Espí
A
A
Balen
E
E
Pardo
F
F
Hernández Lizoaín
J L
JL
Alvarez Cienfuegos
J
J
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010185:Pancreatic Fistula / Q000517:prevention & control; D016577:Pancreaticoduodenectomy / Q000379:methods; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage*
D013004:Somatostatin
Profilaxis con Somatostatina tras duodenopancreatectomía cefálica.